rs138877187

Variant names:

• chr2-166045081-G-A
• rs138877187
• NM_001165963.4:c.1624C>T

Your query was ambiguous. Multiple possible variants found:

• chr2-166045081-G-A
• chr2-166045081-G-C
• chr2-166045081-G-T

Variant summary

Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2 PP3_Strong PP5_Very_Strong

The NM_001353961.2(SCN1A):​c.-802C>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).

• Frequency: Genomes: not found (cov: 32)
• Consequence: SCN1A NM_001353961.2 5_prime_UTR_premature_start_codon_gain
• Clinical Significance: Pathogenic criteria provided, multiple submitters, no conflicts P:7
• Conservation: PhyloP100: 2.22

Genes affected

SCN1A (HGNC:10585): (sodium voltage-gated channel alpha subunit 1) Voltage-dependent sodium channels are heteromeric complexes that regulate sodium exchange between intracellular and extracellular spaces and are essential for the generation and propagation of action potentials in muscle cells and neurons. Each sodium channel is composed of a large pore-forming, glycosylated alpha subunit and two smaller beta subunits. This gene encodes a sodium channel alpha subunit, which has four homologous domains, each of which contains six transmembrane regions. Allelic variants of this gene are associated with generalized epilepsy with febrile seizures and epileptic encephalopathy. Alternative splicing results in multiple transcript variants. The RefSeq Project has decided to create four representative RefSeq records. Three of the transcript variants are supported by experimental evidence and the fourth contains alternate 5' untranslated exons, the exact combination of which have not been experimentally confirmed for the full-length transcript. [provided by RefSeq, Oct 2015]

SCN1A-AS1 (HGNC:54069): (SCN1A and SCN9A antisense RNA 1)

ACMG classification

Verdict is Pathogenic. Variant got 14 ACMG points.

• PM2: Very rare variant in population databases, with high coverage
• PP3: BayesDel_addAF computational evidence supports a deleterious effect, 0.625
• PP5: Variant 2-166045081-G-A is Pathogenic according to our data. Variant chr2-166045081-G-A is described in ClinVar as [Pathogenic]. Clinvar id is 189848.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-166045081-G-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
SCN1A	NM_001165963.4	c.1624C>T	p.Arg542*	stop_gained	Exon 13 of 29	ENST00000674923.1	NP_001159435.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
SCN1A	ENST00000674923.1	c.1624C>T	p.Arg542*	stop_gained	Exon 13 of 29		NM_001165963.4	ENSP00000501589.1
SCN1A	ENST00000303395.9	c.1624C>T	p.Arg542*	stop_gained	Exon 12 of 28	5		ENSP00000303540.4
SCN1A	ENST00000375405.7	c.1624C>T	p.Arg542*	stop_gained	Exon 10 of 26	5		ENSP00000364554.3
SCN1A	ENST00000409050.1	c.1624C>T	p.Arg542*	stop_gained	Exon 10 of 26	5		ENSP00000386312.1

Frequencies

GnomAD3 genomes Cov.: 32

GnomAD4 exome Cov.: 32

GnomAD4 genome Cov.: 32

EpiCase AF: 0.0000545

EpiControl AF: 0.00

ClinVar

Significance: Pathogenic

Submissions summary: Pathogenic:7

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Generalized epilepsy with febrile seizures plus, type 2 Pathogenic:2

Apr 16, 2018

Génétique des Maladies du Développement, Hospices Civils de Lyon

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Jan 17, 2018

Institute of Human Genetics, University of Leipzig Medical Center

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Severe myoclonic epilepsy in infancy Pathogenic:2

Jul 11, 2022

MGZ Medical Genetics Center

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Dec 20, 2014

Center for Bioinformatics, Peking University

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: research

- -

Inborn genetic diseases Pathogenic:1

May 08, 2018

Ambry Genetics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The p.R542* pathogenic mutation (also known as c.1624C>T), located in coding exon 10 of the SCN1A gene, results from a C to T substitution at nucleotide position 1624. This changes the amino acid from an arginine to a stop codon within coding exon 10. This mutation has been detected as a de novo occurrence in an individual with Dravet syndrome and in an individual with severe myoclonic epilepsy of infancy (SMEI) (Mancardi MM et al. Epilepsia, 2006 Oct;47:1629-35; Xu X et al. Brain Dev., 2014 Sep;36:676-81). In addition, in one family, this mutation was inherited from an unaffected mother in two siblings with Dravet syndrome. In this family, the mother was shown to have germline mosaicism for the mutation (Depienne C et al. Hum. Mutat., 2006 Apr;27:389). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -

Early infantile epileptic encephalopathy with suppression bursts Pathogenic:1

Aug 31, 2024

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change creates a premature translational stop signal (p.Arg542*) in the SCN1A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SCN1A are known to be pathogenic (PMID: 17347258, 18930999). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with early infantile epileptic encephalopathy or Dravet syndrome (PMID: 16541393, 17054684, 20522430). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 189848). For these reasons, this variant has been classified as Pathogenic. -

not provided Pathogenic:1

Sep 14, 2024

GeneDx

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 20522430, 30641252, 25459968, 25525159, 25754450, 32090326, 34163418, 31031587, 35074891, 35072530, 31440721, 35813073, 33057194, 35982159, 31864146, 17054684, 37006128, 16541393) -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_addAF	Pathogenic	0.63	D
BayesDel_noAF	Pathogenic	0.32
CADD	Pathogenic	34
DANN	Uncertain	0.98
Eigen	Benign	-0.16
Eigen_PC	Benign	-0.42
FATHMM_MKL	Uncertain	0.93	D
Vest4		0.98, 0.99, 0.98, 0.97
GERP RS		-1.1
RBP_binding_hub_radar		0.0
RBP_regulation_power_radar		1.1

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.0		Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs138877187; hg19: chr2-166901591; COSMIC: COSV57672936;